See how Magnolia Market Access helped a manufacturer overcome coding gaps, payer unfamiliarity, and site readiness challenges to launch the first FDA-approved therapy in a rare disease — creating a replicable, gold-standard access model.
Survey of 100 U.S. physicians uncovers key insights on how international HTA frameworks—especially Germany’s—undervalue chronic disease therapies. Explore the full infographic.
As states expand PDAB authority to set Upper Payment Limits (UPLs) on high-cost therapies, Magnolia Market Access surveyed physicians in Colorado, Maryland, Oregon, and Washington to understand how these policies may affect prescribing decisions, patient care, and clinical operations.
This issue brief provides insights into how 340B savings are being redirected by covered entities—particularly DSH hospitals—toward financial investments instead of patient care, underscoring the urgency of policy changes to realign the program with its mission.
In the June 2025 Navigating Market Access with Magnolia webinar, experts from across the market access ecosystem came together to examine the forces reshaping how manufacturers plan for pricing, reimbursement, and access.
On May 12, 2025, President Trump signed an executive order with the potential to significantly change the U.S. drug pricing and distribution system. Here is what we know about the Administration’s new Most Favored Nation (MFN) policy:
As Medicare Part D plans adopt stricter utilization management, raise cost-sharing, and adjust tier placements, manufacturers face growing challenges in maintaining access. A data-driven formulary coverage assessment helps teams evaluate product positioning, benchmark competitors, and prepare for policy impacts — turning complexity into actionable strategy.
The issue brief explores the PORTAL toolkit for Prescription Drug Affordability Boards (PDABs), highlighting key concerns and potential impacts on drug pricing, patient access, and policy implementation.
While the 340B drug pricing program is often touted as cost-free to taxpayers, our analysis estimates the tax impact of the program for both self- and fully insured employees and workers across the US.
A data analysis comparing growth rates of US inflation and Medicare Part B drug prices (2015-2022) reveals that average sales price (ASP) has grown slower than inflation, making it a more transparent and relevant metric than list prices for evaluating medical spending trends.